| Not Yet Recruiting | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment ccRCC | Phase 2 | 2026-08-01 |
| Not Yet Recruiting | Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma Urothelial Carcinoma | Phase 2 | 2026-06-01 |
| Not Yet Recruiting | A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cyt Advanced Squamous Non-Small Cell Lung Cancer | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | A Prospective Observational Study on of Early-Onset Gastrointestinal Cancer: From Tumor Features to Patient Li Early-onset Gastrointestinal Cancer | — | 2026-04-01 |
| Not Yet Recruiting | Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patien EGFR-mutated NSCLC | — | 2026-02-01 |
| Not Yet Recruiting | XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS Locally Advanced Rectal Cancer (LARC) | Phase 2 | 2026-01-31 |
| Recruiting | Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management NSCLC (Advanced Non-small Cell Lung Cancer), HER2 | — | 2025-08-12 |
| Recruiting | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | 2025-01-24 |
| Recruiting | Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib Metastatic Renal Cell Carcinoma | — | 2024-05-28 |
| Recruiting | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARB Extrapulmonary Small Cell Carcinoma | Phase 2 | 2024-01-16 |
| Recruiting | Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC Pulmonary Large-cell Neuroendocrine Carcinoma | Phase 2 | 2022-05-27 |
| Recruiting | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) Mesotheliomas Pleural | Phase 3 | 2021-12-14 |
| Active Not Recruiting | Alectinib in Neo-adjuvant Treatment of Stage III NSCLC Non Small Cell Lung Cancer | Phase 2 | 2021-05-20 |
| Active Not Recruiting | Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer Colorectal Cancer | — | 2020-10-28 |
| Completed | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung C Small Cell Lung Cancer | Phase 2 | 2020-07-01 |
| Completed | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patie Colorectal Cancer | Phase 2 | 2019-09-26 |
| Completed | Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic The Thromboembolism, Cancer | Phase 4 | 2019-06-27 |
| Completed | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) Non-Small Cell Lung Cancer | Phase 2 | 2019-05-07 |
| Completed | Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Gastric Cancer | Phase 2 | 2018-06-13 |
| Unknown | Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cance Squamous Non-small Cell Lung Cancer | Phase 3 | 2017-09-25 |
| Completed | Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcin Renal Cancer Metastatic | Phase 2 | 2017-07-14 |
| Unknown | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC Small Cell Lung Cancer | Phase 2 | 2017-02-07 |
| Completed | A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirum Mesothelioma | Phase 2 | 2016-12-22 |
| Unknown | Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patie Cancer, Breast | Phase 2 | 2016-11-29 |
| Unknown | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Neuroendocrine Carcinoma | Phase 2 | 2015-05-01 |
| Completed | Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | 2014-02-01 |
| Unknown | Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC Advanced Non-Small Cell Lung Cancer | Phase 2 | 2007-07-01 |
| Completed | Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. Carcinoma, Renal Cell | Phase 3 | 1994-07-01 |